Abstract: The present invention relates to chimeric particles comprising single stranded RNA (ssRNA), double stranded RNA (dsRNA) and at least one cationic agent, a pharmaceutical composition containing said particles and to a method of producing the same. The particles of the present invention are particularly useful as an immunostimulating medicament with a superlative pattern of immunostimulation.
Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.
Type:
Application
Filed:
April 17, 2013
Publication date:
January 16, 2014
Applicant:
BioNTech AG
Inventors:
Ugur Sahin, Ozlem Tureci, Michael Koslowski, Gerd Helftenbein, Dirk Usener, Volker Schluter
Abstract: The present invention relates to modification of RNA with 5?-cap analogs of Formula (1): wherein R1-R6 and n are as described herein, in order to improve the stability and increase the expression of said RNA, in particular in immature antigen presenting cells. The present invention provides a vaccine composition comprising said stabilized RNA, immature antigen presenting cells comprising said stabilized RNA, and methods for stimulating and/or activating immune effector cells and for inducing an immune response in an individual using said stabilized RNA.
Type:
Grant
Filed:
August 3, 2010
Date of Patent:
March 29, 2016
Assignees:
BIONTECH AG, TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH, UNIWERSYTET WARSZAWSKI
Inventors:
Ugur Sahin, Andreas Kuhn, Edward Darzynkiewicz, Jacek Jemielity, Joanna Kowalska